MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galpin, A. J.
Right arrow Articles by Evans, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galpin, A. J.
Right arrow Articles by Evans, W. E.

0026-895X/97/010155-09$3.00/0
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
All rights of reproduction in any form reserved.
MOLECULAR PHARMACOLOGY 52:155-163 (1997).

Differences in Folylpolyglutamate Synthetase and Dihydrofolate Reductase Expression in Human B-Lineage versus T-Lineage Leukemic Lymphoblasts: Mechanisms for Lineage Differences in Methotrexate Polyglutamylation and Cytotoxicity

Amy J. Galpin, John D. Schuetz, Eric Masson, Yuri Yanishevski, Timothy W. Synold, Julio C. Barredo, Ching-Hon Pui, Mary V. Relling, and William E. Evans

Departments of Pharmaceutical Sciences (A.J.G., J.D.S., E.M., Y.Y., T.W.S., M.V.R., W.E.E.) and Hematology-Oncology (C.-H.P.), St. Jude Children's Research Hospital, and the Center for Pediatric Pharmacokinetics and Therapeutics (M.V.R., W.E.E., C.-H.P., J.D.S), Colleges of Pharmacy and Medicine, University of Tennessee, Memphis, Tennessee 38101, and Division of Pediatric Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina (J.C.B.)

Cellular accumulation of methotrexate polyglutamates (MTXPGs) is recognized as an important determinant of the cytotoxicity and selectivity of methotrexate in acute lymphoblastic leukemia (ALL). We identified a significantly lower cellular accumulation of MTXPGs in T-lineage versus B-lineage lymphoblasts in children with ALL, which is consistent with the worse prognosis of T-lineage ALL when treated with conventional antimetabolite-based therapy. Maximum MTXPG accumulation in leukemic blasts in vivo was 3-fold greater in lymphoblasts of children with B-lineage ALL (129 children) compared with those with T-lineage ALL (20 children) (p < 0.01) and was characterized by a saturable (Emax) model in both groups. The human leukemia cell lines NALM6 (B-lineage) and CCRF/CEM (T-lineage) were used to assess potential mechanisms for these lineage differences in MTX accumulation, revealing i) greater total and long-chain MTXPG accumulation in NALM6 over a wide range of methotrexate concentrations (0.2-100 µM), ii) saturation of MTXPG accumulation in both cell lines, with a higher maximum (Emax) in NALM6, iii) 3-fold higher constitutive FPGS mRNA expression and enzyme activity in NALM6 cells, iv) 2-fold lower levels of DHFR mRNA and protein in NALM6 cells, and v) 4-6 fold lower extracellular MTX concentration and 2-fold lower intracellular MTXPG concentration to produce equivalent cytotoxicity (LC50) in NALM6 versus CEM. There was a significant relationship between FPGS mRNA and enzyme activity in lymphoblasts from children with newly diagnosed ALL, and blast FPGS mRNA and activity increased after methotrexate treatment. These data indicate higher FPGS and lower DHFR levels as potential mechanisms contributing to greater MTXPG accumulation and cytotoxicity in B-lineage lymphoblasts.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
S. L. Hider, I. N. Bruce, and W. Thomson
The pharmacogenetics of methotrexate
Rheumatology, October 1, 2007; 46(10): 1520 - 1524.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Ge, C. L. Haska, K. LaFiura, M. Devidas, S. B. Linda, M. Liu, R. Thomas, J. W. Taub, and L. H. Matherly
Prognostic Role of the Reduced Folate Carrier, the Major Membrane Transporter for Methotrexate, in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group
Clin. Cancer Res., January 15, 2007; 13(2): 451 - 457.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. D. Cole, R. A. Drachtman, A. K. Smith, S. Cate, R. A. Larson, D. S. Hawkins, J. Holcenberg, K. Kelly, and B. A. Kamen
Phase II Trial of Oral Aminopterin for Adults and Children with Refractory Acute Leukemia
Clin. Cancer Res., November 15, 2005; 11(22): 8089 - 8096.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Fotoohi, G. Jansen, Y. G. Assaraf, L. Rothem, M. Stark, I. Kathmann, J. Gregorczyk, G. J. Peters, and F. Albertioni
Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy
Blood, December 15, 2004; 104(13): 4194 - 4201.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
J van der Heijden, M C de Jong, B A C Dijkmans, W F Lems, R Oerlemans, I Kathmann, C G Schalkwijk, G L Scheffer, R J Scheper, and G Jansen
Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNF{alpha}
Ann Rheum Dis, February 1, 2004; 63(2): 138 - 143.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Plummer, C. Rees, A. Hughes, P. Beale, M. Highley, J. Trigo, S. Gokul, I. Judson, H. Calvert, A. Jackman, et al.
A Phase I Trial of ZD9331, a Water-Soluble, Nonpolyglutamatable, Thymidylate Synthase Inhibitor
Clin. Cancer Res., April 1, 2003; 9(4): 1313 - 1322.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P Ranganathan, S Eisen, W M Yokoyama, and H L McLeod
Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?
Ann Rheum Dis, January 1, 2003; 62(1): 4 - 9.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Panetta, A. Wall, C.-H. Pui, M. V. Relling, and W. E. Evans
Methotrexate Intracellular Disposition in Acute Lymphoblastic Leukemia: A Mathematical Model of {gamma}-Glutamyl Hydrolase Activity
Clin. Cancer Res., July 1, 2002; 8(7): 2423 - 2429.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. D. Cole, B. A. Kamen, R. Gorlick, D. Banerjee, A. K. Smith, E. Magill, and J. R. Bertino
Effects of Overexpression of {{gamma}}-Glutamyl Hydrolase on Methotrexate Metabolism and Resistance
Cancer Res., June 1, 2001; 61(11): 4599 - 4604.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Leclerc and J. C. Barredo
Folylpoly-{{gamma}}-glutamate Synthetase Gene mRNA Splice Variants and Protein Expression in Primary Human Leukemia Cells, Cell Lines, and Normal Human Tissues
Clin. Cancer Res., April 1, 2001; 7(4): 942 - 951.
[Abstract] [Full Text]

Home page
 ASH Education BookHome page
C. A. Felix, B. J. Lange, and J. M. Chessells
Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000
Hematology, January 1, 2000; 2000(1): 285 - 302.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. G. Rots, R. Pieters, G. J. Peters, C. H. van Zantwijk, R. Mauritz, P. Noordhuis, J. C. Willey, K. Hahlen, U. Creutzig, G. Janka-Schaub, et al.
Circumvention of Methotrexate Resistance in Childhood Leukemia Subtypes by Rationally Designed Antifolates
Blood, November 1, 1999; 94(9): 3121 - 3128.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. M. Belkov, E. Y. Krynetski, J. D. Schuetz, Y. Yanishevski, E. Masson, S. Mathew, S. Raimondi, C.-H. Pui, M. V. Relling, and W. E. Evans
Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation
Blood, March 1, 1999; 93(5): 1643 - 1650.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. G. Rots, R. Pieters, G. J. Peters, P. Noordhuis, C. H. van Zantwijk, G. J.L. Kaspers, K. Hahlen, U. Creutzig, A. J.P. Veerman, and G. Jansen
Role of Folylpolyglutamate Synthetase and Folylpolyglutamate Hydrolase in Methotrexate Accumulation and Polyglutamylation in Childhood Leukemia
Blood, March 1, 1999; 93(5): 1677 - 1683.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. G. Rots, R. Pieters, G.-J. L. Kaspers, C. H. van Zantwijk, P. Noordhuis, R. Mauritz, A. J.P. Veerman, G. Jansen, and G. J. Peters
Differential Methotrexate Resistance in Childhood T- Versus Common/PreB-Acute Lymphoblastic Leukemia Can Be Measured by an In Situ Thymidylate Synthase Inhibition Assay, But Not by the MTT Assay
Blood, February 1, 1999; 93(3): 1067 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C.-H. Pui and W. E. Evans
Acute Lymphoblastic Leukemia
N. Engl. J. Med., August 27, 1998; 339(9): 605 - 615.
[Full Text] [PDF]

Home page
 NEJMHome page
W. E. Evans, M. V. Relling, J. H. Rodman, W. R. Crom, J. M. Boyett, and C.-H. Pui
Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia
N. Engl. J. Med., February 19, 1998; 338(8): 499 - 505.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
Y. Y. Hon and W. E. Evans
Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach
Clin. Chem., February 1, 1998; 44(2): 388 - 400.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics